Search results for: RUSH sequencing service
#29221887 // Save this To Up
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.The fixed-dose combination of sofosbuvir/velpatasvir was highly efficacious in patients infected with genotype (GT)1-6 hepatitis C virus (HCV) in the ASTRAL studies. This analysis evaluated the impact of baseline resistance-associated substitutions (RASs) on treatment outcome and emergence of RASs in patients infected with HCV GT1-6 who were treated with sofosbuvir/velpatasvir.
2269 related Products with: Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.Syringe pump can be contr Cervical carcinoma tissue Hepatocellular carcinoma HCV core 2 119aa recombin HCV NS3 1192 1456aa recom HCV NS5 2212 2313aa recom PI3-Kɣ Inhibitor, AS-605 PI3-Kɣ Inhibitor, AS-605 FAAH Inhibitor, PF-622 FAAH Inhibitor, PF-622; A FAAH Inhibitor, PF-622 FAAH Inhibitor, PF-622; A
#28714976 // Save this To Up
Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease.We identified rare coding variants associated with Alzheimer's disease in a three-stage case-control study of 85,133 subjects. In stage 1, we genotyped 34,174 samples using a whole-exome microarray. In stage 2, we tested associated variants (P < 1 × 10) in 35,962 independent samples using de novo genotyping and imputed genotypes. In stage 3, we used an additional 14,997 samples to test the most significant stage 2 associations (P < 5 × 10) using imputed genotypes. We observed three new genome-wide significant nonsynonymous variants associated with Alzheimer's disease: a protective variant in PLCG2 (rs72824905: p.Pro522Arg, P = 5.38 × 10, odds ratio (OR) = 0.68, minor allele frequency (MAF)= 0.0059, MAF= 0.0093), a risk variant in ABI3 (rs616338: p.Ser209Phe, P = 4.56 × 10, OR = 1.43, MAF= 0.011, MAF= 0.008), and a new genome-wide significant variant in TREM2 (rs143332484: p.Arg62His, P = 1.55 × 10, OR = 1.67, MAF= 0.0143, MAF= 0.0089), a known susceptibility gene for Alzheimer's disease. These protein-altering changes are in genes highly expressed in microglia and highlight an immune-related protein-protein interaction network enriched for previously identified risk genes in Alzheimer's disease. These genetic findings provide additional evidence that the microglia-mediated innate immune response contributes directly to the development of Alzheimer's disease.
1666 related Products with: Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease.Beta Amyloid (42) ELISA K Beta Amyloid (1 40) ELISA Beta Amyloid (40) ELISA K Beta Amyloid (1 40) ELISA Primary antibody FLIP An Anti 3 DG imidazolone Mon rHIV gp36, soluble Antige rHIV gp41, soluble Antige Liver disease spectrum ti Lung disease spectrum tis Colon disease spectrum ti Rectum disease spectrum (
#28679771 // Save this To Up
Neratinib Efficacy and Circulating Tumor DNA Detection ofMutations inNonamplified Metastatic Breast Cancer.Based on promising preclinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/PR) or stable disease (SD) ≥24 weeks, innonamplified metastatic breast cancer (MBC). Secondary endpoints included progression-free survival (PFS), toxicity, and circulating tumor DNA (ctDNA)detection.Tumor tissue positive forwas required for eligibility. Neratinib was administered 240 mg daily with prophylactic loperamide. ctDNA sequencing was performed retrospectively for 54 patients (14 positive and 40 negative for tumor).Nine of 381 tumors (2.4%) sequenced centrally harbored(lobular 7.8% vs. ductal 1.6%;= 0.026). Thirteen additionalcases were identified locally. Twenty-one of these 22cases were estrogen receptor positive. Sixteen patients [median age 58 (31-74) years and three (2-10) prior metastatic regimens] received neratinib. The CBR was 31% [90% confidence interval (CI), 13%-55%], including one CR, one PR, and three SD ≥24 weeks. Median PFS was 16 (90% CI, 8-31) weeks. Diarrhea (grade 2, 44%; grade 3, 25%) was the most common adverse event. Baseline ctDNA sequencing identified the samein 11 of 14 tumor-positive cases (sensitivity, 79%; 90% CI, 53%-94%) and correctly assigned 32 of 32 informative negative cases (specificity, 100%; 90% CI, 91%-100%). In addition, ctDNAvariant allele frequency decreased in nine of 11 paired samples at week 4, followed by an increase upon progression.Neratinib is active in, nonamplified MBC. ctDNA sequencing offers a noninvasive strategy to identify patients withcancers for clinical trial participation..
2689 related Products with: Neratinib Efficacy and Circulating Tumor DNA Detection ofMutations inNonamplified Metastatic Breast Cancer.Breast cancer tissue arra Breast cancer and matched Breast cancer and matched Breast cancer and matched Breast cancer and matched Breast cancer tissue micr Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer membrane pr Breast cancer (multiple t
#28098162 // Save this To Up
Novel genetic loci associated with hippocampal volume.The hippocampal formation is a brain structure integrally involved in episodic memory, spatial navigation, cognition and stress responsiveness. Structural abnormalities in hippocampal volume and shape are found in several common neuropsychiatric disorders. To identify the genetic underpinnings of hippocampal structure here we perform a genome-wide association study (GWAS) of 33,536 individuals and discover six independent loci significantly associated with hippocampal volume, four of them novel. Of the novel loci, three lie within genes (ASTN2, DPP4 and MAST4) and one is found 200 kb upstream of SHH. A hippocampal subfield analysis shows that a locus within the MSRB3 gene shows evidence of a localized effect along the dentate gyrus, subiculum, CA1 and fissure. Further, we show that genetic variants associated with decreased hippocampal volume are also associated with increased risk for Alzheimer's disease (r=-0.155). Our findings suggest novel biological pathways through which human genetic variation influences hippocampal volume and risk for neuropsychiatric illness.
Serum Creatinine Low Samp Monofluoresceinated manni G418 sulfate (Geneticin d MaestroNano Micro-volume E18 Primary Rat Hippocamp Syringe pump can be contr 0.5 10µl Accumax Smart V 1000 10000µl Accumax Sma 0.1 2.5µl Accumax Smart 5 50µl Accumax Smart Var 10 100µl Accumax Smart V 100 1000µl Accumax Smart
#24922517 // Save this To Up
Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease.Alzheimer's disease is a common debilitating dementia with known heritability, for which 20 late onset susceptibility loci have been identified, but more remain to be discovered. This study sought to identify new susceptibility genes, using an alternative gene-wide analytical approach which tests for patterns of association within genes, in the powerful genome-wide association dataset of the International Genomics of Alzheimer's Project Consortium, comprising over 7 m genotypes from 25,580 Alzheimer's cases and 48,466 controls.
1930 related Products with: Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease.Beta Amyloid (42) ELISA K Beta Amyloid (1 40) ELISA Beta Amyloid (40) ELISA K Beta Amyloid (1 40) ELISA Lymphoma array, together pCAMBIA2300 Vector (No Re Cytokeratin, Wide M.W. R Cytokeratin, Wide M.W. R Cytokeratin, Wide M.W. R Blue Feulgen DNA Ploidy Formalin Solution (20%) Formalin Solution (20%)
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia